News
Public · Published
SRAD: Revenue grew 24% as IMG synergies and prediction markets strengthened growth prospects
SRAD reported third-quarter revenue growth of 24% and a 21% rise in adjusted EBITDA. IMG synergies are ahead of target and prediction markets contributed to growth. The company reaffirmed its 2026 guidance while flagging Brazil uncertainty and a possible MLB lockout as key risks.
Published:
Updated:
What happened
SRAD reported third-quarter revenue growth of 24% and a 21% rise in adjusted EBITDA. IMG synergies are ahead of target and prediction markets contributed to growth. The company reaffirmed its 2026 guidance while flagging Brazil uncertainty and a possible MLB lockout as key risks.
Confirmed
Global impact / market context
Faster revenue and adjusted EBITDA, which means earnings before interest, taxes, depreciation and amortization, show the company is growing profitably. Synergies, or cost and revenue benefits from the IMG deal, beating target suggest the acquisition is paying off sooner than planned, supporting future cash available for reinvestment.
Analyst inference
Reaffirmed 2026 guidance signals management expects current growth to continue despite Brazil uncertainty and a possible MLB lockout, which is a work stoppage that could cut sports content and betting activity. Investors must weigh confirmed momentum against these risks when judging future revenue and costs.
Analyst inference
What to watch
- Watch whether Brazil uncertainty and a possible MLB lockout materialize, since the article names both as key risks that could disrupt revenue from sports content and prediction markets. Confirmed
- Track IMG synergy progress against its stated target, because the article says benefits are ahead of plan; further overdelivery could lower costs or lift revenue beyond current expectations. Proposed
- Monitor whether prediction markets keep contributing to growth, since that contribution is cited alongside IMG synergies; a slowdown there could weaken the 24% revenue growth trend supporting reaffirmed 2026 guidance. Analyst inference
Evidence
- Original source link unavailable